RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$ १५.३०
arrow_upward
+३.०३%(+०.४५) 1D
US$ १५.४०
arrow_upward
+०.६५% (+०.१००)bedtimeAfter hours
Closed: सेप्टेम्बर ४, १६:००:०० GMT-४ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
US$ १५.४८
High
US$ १६.०८
Low
US$ १५.२३
Mkt. cap
१.५१ अरब
Avg. vol.
३०.८६ लाख
Volume
१.१५ करोड
52-wk high
US$ ३९.८९
52-wk low
US$ १३.८१
EPS
-US$ ५.८४
Beta
०.३२
Shares outstanding
९.८६ करोड
No. of employees
१ हजार
Open
US$ १५.४८
High
US$ १६.०८
Low
US$ १५.२३
Mkt. cap
१.५१ अरब
Avg. vol.
३०.८६ लाख
Volume
१.१५ करोड
52-wk high
US$ ३९.८९
52-wk low
US$ १३.८१
EPS
-US$ ५.८४
Beta
०.३२
Shares outstanding
९.८६ करोड
No. of employees
१ हजार
News stories
From web sources and news partners
Timothy Sykes
·
१ दिन पहिले
Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win
Benzinga
·
१ दिन पहिले
This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
MarketBeat
·
१ दिन पहिले
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
Stocktwits
·
२ दिन पहिले
Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows?
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees१.३७ हजार
Founded२०१०
HeadquartersNovato, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websiteultragenyx.com